Sunshine Guojian Pharmaceutical received a Wind ESG A rating, with a total score of 7.91同壁财经·Jun 9 at 03:40 AM688336-2.02%
Innovative drug concept stocks rapidly plummeted, with NEPTUNUS hitting the daily limit, RemeGen falling more than 10%, and many stocks including Cosunter, Rundu Pharma, Sunshine Guojian Pharmaceutical, SL PHARM, and HITECK dropping more than 6%Wallstreetcn·Apr 6 at 08:41 PM512290+1.91%0020380.00%
Pharmaceutical stocks fluctuated and surged, with Getein Biotech hitting the daily limit, RemeGen rising nearly 7%, reaching a historical high. Sunshine Guojian Pharmaceutical, EASTON BIOPHARMACEUTICALS, YKYY, Junshi Biosciences, BeBetter Med, and InventisBio also followed suitWallstreetcn·Mar 16 at 09:28 PM688336-2.02%688513-1.74%
Sunshine Guojian Pharmaceutical: Pfizer has registered two global Phase III clinical trials for the PD-1/VEGF dual antibody PF-08634404 (SSGJ-707) on a certain website, and the final payment remains uncertainZhitong·Nov 3, 2025 at 04:29 AM688336-2.02%
A-share innovative drug concept stocks are active again, Sunshine Guojian Pharmaceutical rose over 10% to a new high, Yatai Pharm had two consecutive limit-ups, WECOME rose over 10%, and Baicheng Pharmaceutical, ALK, and Fushine followed suitZhitong·Nov 2, 2025 at 07:48 PM300878-1.36%300497-3.69%
Midday Review: The Beijing Stock Exchange 50 Index surged over 3% in the first half of the day, with strong performance in AI application sectors such as film and mediaZhitong·Oct 30, 2025 at 10:32 PM688336-2.02%300071-0.50%
Sunshine Guojian Pharmaceutical released its performance for the first three quarters, with a net profit attributable to the parent company of 399 million yuan, a year-on-year increase of 71.15%Zhitong·Oct 23, 2025 at 07:26 AM688336-2.02%
Sunshine Guojian Pharmaceutical: Net profit of 190 million yuan in the first half of 2025, a year-on-year increase of 46.96%Zhitong·Aug 29, 2025 at 07:46 AM688336-2.02%
The concept of innovative drugs is active again, Shen Lian Biomedical has achieved a two-day limit upZhitong·Aug 17, 2025 at 08:37 PM688336-2.02%688098+0.86%
Sunshine Guojian Pharmaceutical: Projects 608 and 613 have both submitted new drug marketing applications to the CDE and have been acceptedZhitong·Jun 19, 2025 at 04:18 AM688336-2.02%
Sunshine Guojian Pharmaceutical: The application for the listing of the new drug recombinant anti-IL-1β humanized monoclonal antibody injection has been acceptedZhitong·Jun 5, 2025 at 07:00 AM688336-2.02%
Sunshine Guojian Pharmaceutical: The company's restructured anti-IL-1β humanized monoclonal antibody injection new drug application has been acceptedWallstreetcn·Jun 5, 2025 at 05:47 AM688336-2.02%
The concept of innovative drugs has strengthened again, with Staidson BioPharm rising over 15%, reaching a three-year highZhitong·May 28, 2025 at 08:42 PM603707+4.25%688336-2.02%
